



## Post Authorisation Assessments

For details of post authorisation assessments prior to 1<sup>st</sup> January 2021,  
please refer to the [EMA](#) website.

### Versican Plus DHPPI/L4 Lyophilisate and Suspension for Suspension for Injection for Dogs

Vm 42058/5083

21 April 2026	Addition of 'Injection site lump', 'Injection site mass' and 'Injection site nodule' to the adverse event section under frequenc category 'Rare'.
27 March 2026	To introduce roller bottles as an alternative to the static cell culture flasks for the Vero cell cultures during the production of CPiV 2 viral antigens.
18 March 2025	Deletion of the EU Local Representatives from the GB texts.
12 December 2024	Addition of two rabbit serum suppliers.
11 November 2024	Approval of mock ups.
06 June 2024	Update of the SPC/QRD based on the EU v9 template and the GB National SPC/QRD template.
14 March 2024	Increase of the maximum batch size for the L4 liquid fraction without process change.
16 February 2023	Addition of a quantitative test for residual rabbit serum albumin in the finished product.
25 January 2023	Addition of a secondary packaging site of a finished product. Addition of a secondary packaging site of a finished product.
16 August 2022	Changes to labelling to include GB details in blue box.
03 June 2021	Change in the manufacturing process of the active substance. Change in the manufacturing process of the active substance.